Background:

The Ret gene products include two glycosylated proteins and, in tunicamycin treated cells, a non-glycosylated protein consistent with the predicted Ret molecular weight based on sequence analysis. Tumor-specific rearrangements of the Ret proto-oncogene have been identified in papillary thyroid carcinomas leading to the formation of different transforming fusion proteins sharing the tyrosine kinase domain of Ret. In contrast to the Ret proto-oncogene, the rearranged forms are constitutively phosphorylated on tyrosine and are translocated from the membrane to the cytoplasm.

Specificity:

RET (Phospho-Y981) polyclonal antibody detects endogenous levels of RET protein only when phosphorylated at Tyr981.

Alternative names:

Proto-oncogene tyrosine-protein kinase receptor Ret; Cadherin family member 12; Proto-oncogene c-Ret; RET; CDHF12; CDHR16; PTC; RET51

Species reactivity:

Human,Mouse,Rat

Host:

Rabbit

Ig type:

Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2

Immunogen:

Synthetic phosphopeptide derived from human RET around the phosphorylation site of Tyrosine 981.

Purification & Purity:

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).

Molecular weight:

~ 175, 124 kDa

Applications:

WB

Usage:

WB: 1:500~1:1000 IHC: 1:50~1:200

Storage:

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Precautions:

For research use only, not for use in diagnostic procedure.

More info:

Email: info@sobekbio.com

Orders:

Email: orders@sobekbio.com